Roche Holding AG (SWX:ROP)
356.80
-4.40 (-1.22%)
Sep 18, 2026, 5:31 PM CET
Roche Holding AG Employees
Roche Holding AG had 103,249 employees as of December 31, 2024. The number of employees decreased by 356 or -0.34% compared to the previous year.
Employees
103,249
Change (1Y)
-356
Growth (1Y)
-0.34%
Revenue / Employee
609.78K CHF
Profits / Employee
119.53K CHF
Market Cap
285.14B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 103,249 | -356 | -0.34% |
| Dec 31, 2023 | 103,605 | -8 | -0.01% |
| Dec 31, 2022 | 103,613 | 2,693 | 2.67% |
| Dec 31, 2021 | 100,920 | -545 | -0.54% |
| Dec 31, 2020 | 101,465 | 3,730 | 3.82% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novartis AG | 75,267 |
| Alcon | 25,000 |
| Lonza Group AG | 20,141 |
| Sandoz Group AG | 20,000 |
| Sonova Holding AG | 18,590 |
| Straumann Holding AG | 11,582 |
| Galderma Group AG | 7,676 |
| Galenica AG | 6,623 |
Roche Holding AG News
- 2 days ago - CHMP recommends EU approval of Roche's Ocrevus for children and adolescents with relapsing multiple sclerosis - GlobeNewsWire
- 3 days ago - Genentech and Roche Announce Grand Opening of Boston R&D Innovation Center - Business Wire
- 3 days ago - Roche announces grand opening of its Innovation Center Boston to drive advancements in Cardiovascular, Renal and Metabolic diseases - GlobeNewsWire
- 3 days ago - Roche's Lunsumio-based regimen significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study - GlobeNewsWire
- 3 days ago - Genentech's Lunsumio-Based Regimen Significantly Improves Progression-Free Survival in Follicular Lymphoma in Phase III CELESTIMO Study - Business Wire
- 8 days ago - Roche's collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer - GlobeNewsWire
- 10 days ago - U.S. FDA Grants Priority Review for Genentech's Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments - Business Wire
- 10 days ago - U.S. FDA grants Priority Review for Roche's Enspryng for MOGAD, an autoimmune disease with no approved treatments - GlobeNewsWire